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Abstract
Podoplanin/aggrus is increased in tumors, and its expression was associated with 
tumor malignancy. Podoplanin on cancer cells serves as a platelet-aggregating 
factor, which is associated with the metastatic potential. However, regulators of 
podoplanin remain to be determined. Transforming growth factor- (TGF-) 
regulates many physiological events including tumorigenesis. Here, we found that 
TGF- induced podoplanin in human fibrosarcoma HT1080 cells, and furthermore 
enhanced the platelet aggregating-ability of HT1080. TGF- type I receptor 
inhibitor (SB431542) and short hairpin Smad4 inhibited the podoplanin induction 
by TGF-. These results suggest that TGF- is a physiological regulator of 
podoplanin in tumor cells
* Abstract
21. Introduction
A mucin-type transmembrane sialoglycoprotein, podoplanin (aggrus) is highly 
expressed in lymphatic endothelial cells (LECs) [1]. Several lines of evidence obtained 
using podoplanin knockout mice suggest that podoplanin is crucially involved in 
lymphatic vessel formation [2]. Moreover, podoplanin is reportedly expressed in 
several tumor cells such as various squamous cell carcinomas, testicular tumors,
mesothelioma, and brain tumors, although podoplanin is not expressed in 
gastrointestinal and pulmonary adenocarcinomas, which frequently undergo metastasis 
[3]. Recent investigations have reinforced the notion that expression of podoplanin is 
associated with tumor malignant progression [4].
Podoplanin belongs to the family of type-I transmembrane sialomucin-like 
glycoproteins and possess the platelet-aggregating activity and metastasis-promoting 
ability [5,6]. The segment of EDxxVTPG in the extracellular domain, designated as a 
platelet aggregation-stimulating (PLAG) domain, is critical for the activity of 
podoplanin. In particular, this motif, which is highly conserved across species, is 
triplicated in tandem [7]. In a study of targeted mutagenesis of podoplanin molecules, 
we obtained evidence that Thr residues in the PLAG domain play an important role in 
platelet aggregation [5]. Recently, we purified human podoplanin from the 
glioblastoma cell line LN319 cells using an anti-human PLAG domain monoclonal 
antibody (NZ-1), and showed that podoplanin possesses a disialyl-core1 structure at 
Thr52 in the PLAG domain [8]. Furthermore, C-type lectin-like receptor 2 (CLEC-2), 
which is a non-classical C-type lectin, was identified as an endogenous receptor of 
podoplanin on platelet [9]. NZ-1 neutralized the association between podoplanin and 
CLEC-2, and suppressed podoplanin-induced platelet aggregation and metastasis [10].
Transforming growth factor- (TGF-) superfamily of extracellular growth factors 
regulates cell proliferation, differentiation, apoptosis, and morphogenesis. Upon ligand 
binding to two different types of serine/threonine kinase receptors, type I receptor is 
activated by type II receptor and transduces intracellular signals by phosphorylation of 
receptor-regulated Smad (R-Smad). Among R-Smad, Smad1, Smad5, and Smad8 are 
3phosphorylated by the bone morphogenetic protein (BMP) receptors, whereas Smad2 
and Smad3 are phosphorylated by the TGF-/activin receptors [11]. Phosphorylated 
R-Smad forms a functional signaling complex with Smad4 and translocates into the 
nucleus to regulate expression of the ligand-responsive genes [12]. TGF- regulates a 
number of genes in a cell type and context dependent manner.
Podoplanin has been reported to be expressed in invading front of tumors cells and 
be involved in tumor invasion [13]; therefore, some stromal factors might be involved 
in the induction of podoplanin. Previously, Interkeukin-3 (IL-3) was reported to induce 
podoplanin in human endothelial cells [14]. However, it has not been clarified how the 
expression of podoplanin is regulated in tumor cells. In this study, we examined the 
expression of podoplanin by TGF- using various cell lines.
42. Materials and methods
2. 1. Cells and reagents
HT1080, 293T, HaCaT, and MCF10A cells were obtained from the American 
Type Culture Collection (ATCC). These cells were cultured in Dulbecco’s modified 
Eagle’s medium (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum 
(Sigma) and 1% of penicillin-streptomycin solution (Invitrogen Corp., Carlsbad, CA).
Puromycin and SB431542 was obtained from Sigma and Calbiochem Novabiochem 
Corp. (San Diego, CA), respectively. TGF- was purchased from R&D Systems 
(Minneapolis, MN).
2. 2. DNA constructs
Sequence of oligonucleotides against human Smad4 cDNA was as follows: 
GGATTTCCTCATGTGATCT. The complementary oligonucleotides were annealed and 
ligated in a pSUPER. puro vector (OligoEngine, Seattle, WA). Stable HT1080 clones 
transfected with pSUPER-short hairpin RNAs for Smad4 (shSmad4) were selected and 
maintained in the presence of puromycin (1 µg/ml).
2. 3. Reverse transcription (RT)-PCR
Total RNA was prepared using Isogen (Nippongene Co., Ltd., Tokyo, Japan). 
Reverse transcription was performed with Superscript III (Invitrogen Corp.), and PCR 
was performed using the primers listed as follows: podoplanin:
5’-CCAGGAGAGCAACAACTCAA-3’ (forward), 
5’-GATGCGAATGCCTGTTACAC-3’ (reverse); Smad7: 
5’-GGAAGTCAAGAGGCTGTGTT-3’ (forward), 
5’-GCTTTCTCCTCCCAGTATGC-3’ (reverse); -actin:
5’-CAAGAGATGGCCACGGCTGCT-3’ (forward), 
5’-TCCTTCTGCATCCTGTCGGCA-3’ (reverse).
2. 4. Luciferase assay
5Cells were transfected with (CAGA)9 MLP-luc using FuGENE6 (Roche 
Diagnostics K.K., Tokyo, Japan). Luciferase activities were determined by Luciferase 
Assay Systems (Promega K.K., Tokyo, Japan) and normalized to -galactosidase 
activity of co-transfected CH110 (GE Healthcare UK Ltd., Buckinghamshire, UK).
2. 5. Flow cytometry
Expression levels of human podoplanin were compared for confirmation 
using flow cytometry. HT1080 cells, which were collected by trypsin-EDTA treatment, 
were incubated with NZ-1 (0.1 µg/ml) for 1 h at 4 °C. Then the cells were incubated 
with Oregon green-conjugated anti-rat antibodies (Invitrogen Corp.) for 30 min. Flow 
cytometry was performed using FACS Caliber (BD Biosciences, Barintree, MA).
2. 6. Western-blot analysis
The cell lines were solubilized with lysis buffer (1% Triton in PBS) and 
electrophoresed under reducing conditions on 10–20% polyacrylamide gels. The 
separated proteins were transferred to a PVDF membrane. After blocking with 4% skim 
milk in PBS, the membrane was incubated with NZ-1 (rat; 0.1 µg/ml), anti-Smad2 
(mouse; 0.25 µg/ml; Transduction Laboratories, Lexington, KY), anti-Smad4 (mouse; 
0.2 µg/ml; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-phospho-Smad2
(rabbit) [15], and anti--actin antibody (mouse, 0.2 µg/ml; Sigma), and then with 
peroxidase-conjugated anti-rat, anti-mouse, or anti-rabbit antibodies (1/1000 diluted; 
GE Healthcare UK Ltd.), and developed for 1 min with ECL reagents (GE Healthcare 
UK Ltd.) using Kodak X-Omat AR film.
2. 7. Platelet aggregation assay by WBA Carna
Heparinized human whole blood (WB) was drawn from healthy drug-free 
volunteers. Platelet aggregation was measured according to the screen filtration 
pressure method using WBA Carna (IMI, Saitama, Japan) [3,8,10]. Two hundred 
microliters each of human whole blood samples in four reaction tubes were stirred at 
61,000 r.p.m. at 37°C and pre-incubated for 1 min, followed by addition of 10 µl each of 
HT1080 cells (1 x 105 cells or 4 x 104). Using a 3.7-mm-diameter syringe containing 
screen microsieves made of nickel, with 300 openings of 20 x 20 µm2 in a 1 
mm-diameter area, WB samples were sucked to detect aggregation pressure at a rate of 
200 µl/6.4 s 2 min later. The final platelet aggregation pressure of each reaction tube 
was determined at the pressure rate (%) of a pressure sensor connected to the syringe.
2.8. Statistical analyses
Results are expressed as the mean ± standard deviation. Student’s t-test was 
used to determine significance among the groups. A value of p < 0.05 was considered 
significant.
73. Results and discussion
3.1. Induction of podoplanin by TGF- in hunan fibrosarcoma HT1080 cells.
To examine the expression of podoplanin by TGF-, we performed 
western-blot analysis using anti-podoplanin monoclonal antibody, NZ-1 [3] in various 
cell lines. As shown in Fig. 1A, TGF- induced podoplanin in human fibrosarcoma 
HT1080 cells, but not in breast epithelial MCF-10A cells and human keratinocyte, 
HaCaT cells, which are known to exhibit the high responsiveness to TGF-. Although 
human embryonic kidney 293T cells express low level of podoplanin, the induction of 
podoplanin by TGF- was hardly observed. Time course experiment showed that 
podoplanin mRNA increased at 12 hours’ treatment with TGF- (Fig. 1B), followed by 
the podoplanin protein at 24 hours (Fig. 1C). Induction of Smad7 which is a target gene 
of TGF- signaling, were observed in HT1080 cells, indicating that TGF--Smad 
signaling pathway is intact in HT1080 cells (Fig. 1B). Phosphorylation of Smad2 by 
TGF- was also detected (Fig. 1C). Furthermore, we found that SB431542, a selective 
inhibitor of TGF- type I receptor, inhibited the induction of podoplanin by TGF- in a 
dose dependent manner (Fig. 1D). These results indicated that TGF- stimulates 
podoplanin expression in HT1080 cells. 
TGF- is a potent growth inhibitor with tumor-suppressing activity. Cancer 
cells often show resistance to this growth inhibition either because of genetic loss of 
TGF- signaling components or, more commonly, because of downstream perturbation 
of the signaling pathway, such as by Ras activation [16]. Carcinomas often secrete 
excess TGF- and respond to it by enhanced invasion and metastasis [17]. TGF- is 
known to induce epithelial-mesenchymal transition (EMT) through the induction of 
SIP1 andδEF1 [18], Snail family transcriptional factors [19], and the suppression of 
inhibitor of DNA binding (Id) proteins [20]. Furthermore, TGF- promotes bone 
metastasis through the induction of IL-11 and connective tissue growth factor [21].
Podoplanin has been also reported to induce EMT in MDCK cells linked to the 
activation of RhoA, and increased cell migration and invasiveness [13]. Although 
TGF- induces podoplanin in HT1080 cells, it is not sufficient to induce the invasion 
8and migration of HT1080 cells [22]. Even though, podoplanin might be one of cancer 
progressive factor, which is regulated by TGF-.
3.2. Platelet aggregation by HT1080 cells.
To confirm the expression of functional podoplanin on cell surface, we 
performed the flow cytometry using anti-podoplanin (NZ-1). As shown in Fig. 2A, the 
expression of podoplanin on cell surface was observed in the absence of TGF- and its 
expression was further stimulated by TGF-. We next investigated the platelet 
aggregation by HT1080 cells in the presence or absence of TGF-. Platelet aggregation 
was observed in control HT1080 cells, and was further stimulated by TGF--treated 
HT1080 cells (Fig. 2B). These results suggest that functional podoplanin was induced 
on cell surface of HT1080 cells.
3.3. Effect of Smad4 knockdown on the induction of podoplanin by TGF-.
We next investigated the involvement of Smad pathway on the expression of 
podoplanin by TGF-. We established HT1080 cells which stably expressed short 
hairpin RNAs for Smad4 (shSmad4). We obtained two transfectants (clone 5 and 10), 
and these Smad4 were significantly reduced compared with control (pSUPER) 
transfected cells (Fig. 3A). However, the expression of Smad2 and phosphorylation of 
Smad2 by TGF- were similar between control and shSmad4 transfected cells. The 
transcriptional activation of (CAGA)9 MLP-luc by TGF- was significantly reduced in 
shSmad4 transfected cells (Fig. 3B). Using these transfectants, we investigated the 
induction of podoplanin by TGF-. As shown in Fig. 3C, the induction of podoplanin by 
TGF- was blocked in shSmad4 transfected cells. These results suggest that 
TGF--Smad pathway is important for the induction of podoplanin by TGF- in 
HT1080 cells. 
TGF- regulates various target genes via Smad pathway [23]. However, 
podoplanin was not induced by TGF- in HaCaT and MCF10A cells (Fig. 1A), which 
suggested that TGF--Smad signaling alone is not sufficient to induce podoplanin. 
Therefore, Smad would cooperatively regulate podoplanin with other transcriptional 
9factors, which maintain the basal expression of podoplanin in HT1080 cells. Recent 
report revealed that transcriptional factor Sp1 and Sp3 stimulate basal podoplanin 
expression, and methylation status of its promoter confers cell-type specific podoplanin 
expression [24]. Smads have been shown to interact with Sp1, and regulates various 
target genes including p21 [25]. Further study is needed to identify the transcriptional 
factors which regulate podoplanin with Smads.
In conclusion, we found that TGF- induced podoplanin in human 
fibrosarcoma HT1080 cells. The platelet aggregation by HT1080 cells was stimulated 
by treatment of cells with TGF-, which may lead to acquirement of high metastatic 
ability of cancer cells. Furthermore, we are now investigating whether podoplanin is 
induced by TGF- in other cancer cells. In the future, podoplanin and TGF- might 
represent a promising therapeutic target in cancer invasion and metastasis.
10
Acknowledgements 
We thank Ms. Nana Matsuura for technical assistance. This study was supported in part 
by grants-in-aid for Scientific Research from the Ministry of Education, Culture, 
Science, Sports and Technology of Japan (H. Suzuki), by Mitsubishi Pharma Research 
Foundation (Y. Kato), and by the YASUDA Medical Foundation (Y. Kato).
11
References
[1] Breiteneder-Geleff, S., Matsui, K., Soleiman, A., Meraner, P., Poczewski, H., 
Kalt, R., Schaffner, G., and Kerjaschki, D. (1997). Podoplanin, novel 43-kd 
membrane protein of glomerular epithelial cells, is down-regulated in 
puromycin nephrosis. Am J Pathol. 151, 1141-1152.
[2] Schacht, V., Ramirez, M.I., Hong, Y.K., Hirakawa, S., Feng, D., Harvey, N., 
Williams, M., Dvorak, A.M., Dvorak, H.F., Oliver, G., and Detmar, M. (2003). 
T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature 
formation and causes lymphedema. Embo J. 22, 3546-3556.
[3] Kato, Y., Kaneko, M.K., Kuno, A., Uchiyama, N., Amano, K., Chiba, Y., 
Hasegawa, Y., Hirabayashi, J., Narimatsu, H., Mishima, K., and Osawa, M. 
(2006). Inhibition of tumor cell-induced platelet aggregation using a novel 
anti-podoplanin antibody reacting with its platelet-aggregation-stimulating 
domain. Biochem Biophys Res Commun. 349, 1301-1307.
[4] Mishima, K., Kato, Y., Kaneko, M.K., Nishikawa, R., Hirose, T., and Matsutani, 
M. (2006). Increased expression of podoplanin in malignant astrocytic tumors 
as a novel molecular marker of malignant progression. Acta Neuropathol (Berl).
111, 483-488.
[5] Kato, Y., Fujita, N., Kunita, A., Sato, S., Kaneko, M., Osawa, M., and Tsuruo, T. 
(2003). Molecular identification of Aggrus/T1alpha as a platelet 
aggregation-inducing factor expressed in colorectal tumors. J. Biol. Chem. 278, 
51599-51605.
[6] Kaneko, M., Kato, Y., Kunita, A., Fujita, N., Tsuruo, T., and Osawa, M. (2004). 
Functional sialylated O-glycan to platelet aggregation on Aggrus 
(T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells. J 
Biol Chem. 279, 38838-38843.
[7] Kaneko, M.K., Kato, Y., Kitano, T., and Osawa, M. (2006). Conservation of a 
platelet activating domain of Aggrus/podoplanin as a platelet 
aggregation-inducing factor. Gene. 378, 52-57.
[8] Kaneko, M.K., Kato, Y., Kameyama, A., Ito, H., Kuno, A., Hirabayashi, J., 
12
Kubota, T., Amano, K., Chiba, Y., Hasegawa, Y., Sasagawa, I., Mishima, K., 
and Narimatsu, H. (2007). Functional glycosylation of human podoplanin: 
glycan structure of platelet aggregation-inducing factor. FEBS Lett. 581, 
331-336.
[9] Suzuki-Inoue, K., Kato, Y., Inoue, O., Kaneko, M.K., Mishima, K., Yatomi, Y., 
Narimatsu, H., and Ozaki, Y. (2007). Involvement of the snake toxin receptor 
CLEC-2 in podoplanin-mediated platelet activation by cancer cells. J Biol 
Chem. 282, 25993-26001.
[10] Kato, Y., Kaneko, M.K., Kunita, A., Ito, H., Kameyama, A., Ogasawara, S., 
Matsuura, N., Hasegawa, Y., Suzuki-Inoue, K., Inoue, O., Ozaki, Y., and 
Narimatsu, H. (2008). Molecular analysis of the pathophysiological binding of 
the platelet aggregation-inducing factor podoplanin to the C-type lectin-like 
receptor CLEC-2. Cancer Sci. 99, 54-61.
[11] Heldin, C.H., Miyazono, K., and ten Dijke, P. (1997). TGF-beta signalling from 
cell membrane to nucleus through SMAD proteins. Nature. 390, 465-471.
[12] Massague, J., Seoane, J., and Wotton, D. (2005). Smad transcription factors. 
Genes Dev. 19, 2783-2810.
[13] Martin-Villar, E., Megias, D., Castel, S., Yurrita, M.M., Vilaro, S., and 
Quintanilla, M. (2006). Podoplanin binds ERM proteins to activate RhoA and 
promote epithelial-mesenchymal transition. J Cell Sci. 119, 4541-4553.
[14] Groger, M., Loewe, R., Holnthoner, W., Embacher, R., Pillinger, M., Herron, 
G.S., Wolff, K., and Petzelbauer, P. (2004). IL-3 induces expression of 
lymphatic markers Prox-1 and podoplanin in human endothelial cells. J 
Immunol. 173, 7161-7169.
[15] Goumans, M.J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P., and ten 
Dijke, P. (2002). Balancing the activation state of the endothelium via two 
distinct TGF-beta type I receptors. Embo J. 21, 1743-1753.
[16] Chen, C.R., Kang, Y., and Massague, J. (2001). Defective repression of c-myc 
in breast cancer cells: A loss at the core of the transforming growth factor beta 
growth arrest program. Proc Natl Acad Sci U S A. 98, 992-999.
13
[17] Akhurst, R.J., and Derynck, R. (2001). TGF-beta signaling in cancer--a
double-edged sword. Trends Cell Biol. 11, S44-51.
[18] Shirakihara, T., Saitoh, M., and Miyazono, K. (2007). Differential regulation of 
epithelial and mesenchymal markers by deltaEF1 proteins in epithelial 
mesenchymal transition induced by TGF-beta. Mol Biol Cell. 18, 3533-3544.
[19] Peinado, H., Quintanilla, M., and Cano, A. (2003). Transforming growth factor 
beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for 
epithelial mesenchymal transitions. J Biol Chem. 278, 21113-21123.
[20] Kondo, M., Cubillo, E., Tobiume, K., Shirakihara, T., Fukuda, N., Suzuki, H., 
Shimizu, K., Takehara, K., Cano, A., Saitoh, M., and Miyazono, K. (2004). A 
role for Id in the regulation of TGF-beta-induced epithelial-mesenchymal 
transdifferentiation. Cell Death Differ. 11, 1092-1101.
[21] Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, 
C., Guise, T.A., and Massague, J. (2003). A multigenic program mediating 
breast cancer metastasis to bone. Cancer Cell. 3, 537-549.
[22] Kwak, H.J., Park, M.J., Cho, H., Park, C.M., Moon, S.I., Lee, H.C., Park, I.C., 
Kim, M.S., Rhee, C.H., and Hong, S.I. (2006). Transforming growth 
factor-beta1 induces tissue inhibitor of metalloproteinase-1 expression via 
activation of extracellular signal-regulated kinase and Sp1 in human 
fibrosarcoma cells. Mol Cancer Res. 4, 209-20.
[23] Massague, J., Blain, S.W., and Lo, R.S. (2000). TGFbeta signaling in growth 
control, cancer, and heritable disorders. Cell. 103, 295-309.
[24] Hantusch, B., Kalt, R., Krieger, S., Puri, C., and Kerjaschki, D. (2007). 
Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of 
human podoplanin in MG63 versus Saos-2 osteoblastic cells. BMC Mol Biol. 8, 
20.
[25] Moustakas, A., and Kardassis, D. (1998). Regulation of the human 
p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between 
Sp1 and Smad family members. Proc Natl Acad Sci U S A. 95, 6733-6738.
14
Figure legends
Fig. 1 Induction of podoplanin by TGF- in human fibrosarcoma HT1080 cells. 
(A) HaCaT, 293T, HT1080, and MCF10A cells were treated with TGF- (2.5 ng/ml) 
for 24 hours. Western-blot analysis was performed using anti-podoplanin antibody 
(NZ-1). The -actin protein is used as a loading control. (B and C) HT1080 cells were 
treated with TGF- for indicated time periods. (B) Semi-quantitative RT-PCR analysis 
was performed to detect podoplanin and Smad7 mRNA. -actin is used as internal 
control. (C) Western-blot analysis was performed using NZ-1, anti-phospho-Smad2, 
anti-Smad2, and anti--actin antibodies. (D) HT1080 cells were treated with TGF- in 
the presence or absence of SB431542 at indicated concentrations for 24 hours. 
Western-blot analysis was performed using antibodies as indicated. D indicates 
dimethyl sulfoxide (solvent).
Fig. 2 Cell surface expression of podoplanin and platelet aggregation by HT1080 
cells. (A) Flow cytometric analyses of NZ-1 to HT1080 cells which were treated with 
TGF- for 24 hours. (B) Platelet aggregation was measured using WBA Carna with the 
screen filtration pressure method. Data are means ± SD of three independent 
experiments.
Fig. 3 Effect of Smad4 knockdown on the TGF--induced podoplanin expression. 
(A) Western-blot analysis of Smad4 in shSmad4-transfected HT1080 cells (clone 5 and 
10). Cells were treated with TGF-for 1 hour. Western-blot analysis was performed 
using anti-Smad4, anti-phospho-Smad2, anti-Smad2, and anti--actin antibodies. (B) 
(CAGA)9 MLP-luc activation by TGF- was inhibited in shSmad4-transfected cells. 
Cells were transfected with (CAGA)9 MLP-luc for 24 hours and treated with 
TGF-for another 24 hours. Luciferase activity was determined as described in 
Materials and methods. Error bars represent mean  S.D. (C) Effect of Smad4 
knockdown on the TGF--induced podoplanin expression. Cells were treated with 
TGF-for 24 hours. Western-blot analysis was performed using NZ-1 and anti--actin 
antibodies.
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